Mazdutide Explored as Potential Treatment for Alcohol Use Disorder in Phase 2 Trial
Background
Alcohol Use Disorder (AUD) is a chronic relapsing brain disease characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It affects millions globally, yet current pharmacological treatments have limited efficacy and adherence. This study addresses the urgent need for novel, effective therapeutic strategies to manage AUD, investigating a new approach with Mazdutide.
Results
This Phase 2 study is currently active and not yet recruiting, meaning no efficacy or safety results have been published. Researchers aim to determine if Mazdutide, a dual GLP-1/GIP receptor agonist, can significantly reduce behaviors associated with Alcohol Use Disorder (AUD) compared to placebo. The primary objective is to assess changes in alcohol consumption patterns and related behaviors using the Timeline Followback method by Week 28. > The study is designed to identify a statistically significant difference in AUD-related behaviors, such as heavy drinking days or total alcohol consumption, between the Mazdutide and placebo groups, providing crucial proof-of-concept data for future development. Secondary outcomes will explore safety, tolerability, and other alcohol-related metrics.
Why It Matters
If successful, this study could establish Mazdutide as a promising new therapeutic option for Alcohol Use Disorder (AUD), potentially offering a novel mechanism of action (via GLP-1/GIP agonism affecting reward pathways) compared to existing treatments. A positive outcome would pave the way for larger Phase 3 clinical trials, bringing a new, potentially more effective, and better-tolerated treatment closer to patients struggling with AUD. This could significantly improve patient outcomes and quality of life.